CDK1 and prostate cancer: For example, in prostate cancer cells, aberrant activation of CDK1 was found to promote cell proliferation as well as survival by virtue of phosphorylation and inhibition of FOXO1 that prolonged the transition from G2 to M phase and functioned as a tumor suppressor, thus contributing to tumorigenesis.